# Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

> **NCT00223938** · PHASE4 · TERMINATED · sponsor: **Sanofi** · enrollment: 112 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Oral Iron
- **DRUG:** sodium ferric gluconate
- **DRUG:** sodium ferric gluconate

## Key facts

- **NCT ID:** NCT00223938
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-12-30
- **Primary completion:** 2007-04-27
- **Final completion:** 2007-04-27
- **Target enrollment:** 112 (ACTUAL)
- **Why stopped:** The study was terminated because of significant enrollment challenges
- **Last updated:** 2021-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00223938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00223938, "Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00223938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*